Literature DB >> 22864477

Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation.

David Nittner1, Irina Lambertz, Frederic Clermont, Pieter Mestdagh, Corinna Köhler, Søren Jensby Nielsen, Aart Jochemsen, Frank Speleman, Jo Vandesompele, Michael A Dyer, Alexander Schramm, Johannes H Schulte, Jean-Christophe Marine.   

Abstract

Synthetic lethality is a promising strategy for specific targeting of cancer cells that carry mutations that are absent in normal cells. This approach may help overcome the challenge associated with targeting dysfunctional tumour suppressors, such as p53 and Rb (refs 1, 2). Here we show that Dicer1 targeting prevents retinoblastoma formation in mice by synthetic lethality with combined inactivation of p53 and Rb. Although Dicer1 functions as a haploinsufficient tumour suppressor, its complete loss of function is selected against during tumorigenesis(3-5). We show that Dicer1 deficiency is tolerated in Rb-deficient retinal progenitor cells harbouring an intact p53 pathway, but not in the absence of p53. This synthetic lethality is mediated by the oncogenic miR-17-92 cluster because its deletion phenocopies Dicer1 loss in this context. miR-17-92 inactivation suppresses retinoblastoma formation in mice and co-silencing of miR-17/20a and p53 cooperatively decreases the viability of human retinoblastoma cells. These data provide an explanation for the selective pressure against loss of Dicer1 during tumorigenesis and a proof-of-concept that targeting miRNAs may potentially represent a general approach for synthetic lethal targeting of cancer cells that harbour specific cancer-inducing genotypes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22864477     DOI: 10.1038/ncb2556

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  37 in total

1.  Essential role for Dicer during skeletal muscle development.

Authors:  Jason R O'Rourke; Sara A Georges; Howard R Seay; Stephen J Tapscott; Michael T McManus; David J Goldhamer; Maurice S Swanson; Brian D Harfe
Journal:  Dev Biol       Date:  2007-08-25       Impact factor: 3.582

2.  Reduced expression of Dicer associated with poor prognosis in lung cancer patients.

Authors:  Yoko Karube; Hisaaki Tanaka; Hirotaka Osada; Shuta Tomida; Yoshio Tatematsu; Kiyoshi Yanagisawa; Yasushi Yatabe; Junichi Takamizawa; Shinichiro Miyoshi; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Sci       Date:  2005-02       Impact factor: 6.716

3.  Role of Mdm4 in drug sensitivity of breast cancer cells.

Authors:  S Lam; K Lodder; A F A S Teunisse; M J W E Rabelink; M Schutte; A G Jochemsen
Journal:  Oncogene       Date:  2010-02-08       Impact factor: 9.867

4.  MicroRNA biogenesis is required for Myc-induced B-cell lymphoma development and survival.

Authors:  Maria Pia Arrate; Tiffaney Vincent; Jessica Odvody; Rekha Kar; Stephen N Jones; Christine M Eischen
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

5.  Cooperation between Rb and Arf in suppressing mouse retinoblastoma.

Authors:  Karina Conkrite; Maggie Sundby; David Mu; Shizuo Mukai; David MacPherson
Journal:  J Clin Invest       Date:  2012-04-09       Impact factor: 14.808

6.  Inactivation of the p53 pathway in retinoblastoma.

Authors:  Nikia A Laurie; Stacy L Donovan; Chie-Schin Shih; Jiakun Zhang; Nicholas Mills; Christine Fuller; Amina Teunisse; Suzanne Lam; Yolande Ramos; Adithi Mohan; Dianna Johnson; Matthew Wilson; Carlos Rodriguez-Galindo; Micaela Quarto; Sarah Francoz; Susan M Mendrysa; R Kiplin Guy; Jean-Christophe Marine; Aart G Jochemsen; Michael A Dyer
Journal:  Nature       Date:  2006-11-02       Impact factor: 49.962

7.  Dicer inactivation leads to progressive functional and structural degeneration of the mouse retina.

Authors:  Devid Damiani; John J Alexander; Jason R O'Rourke; Mike McManus; Ashutosh P Jadhav; Constance L Cepko; William W Hauswirth; Brian D Harfe; Enrica Strettoi
Journal:  J Neurosci       Date:  2008-05-07       Impact factor: 6.167

8.  MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc.

Authors:  Baltazar D Aguda; Yangjin Kim; Melissa G Piper-Hunter; Avner Friedman; Clay B Marsh
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-09       Impact factor: 11.205

9.  Compensation by tumor suppressor genes during retinal development in mice and humans.

Authors:  Stacy L Donovan; Brett Schweers; Rodrigo Martins; Dianna Johnson; Michael A Dyer
Journal:  BMC Biol       Date:  2006-05-03       Impact factor: 7.431

10.  RDML: structured language and reporting guidelines for real-time quantitative PCR data.

Authors:  Steve Lefever; Jan Hellemans; Filip Pattyn; Daniel R Przybylski; Chris Taylor; René Geurts; Andreas Untergasser; Jo Vandesompele
Journal:  Nucleic Acids Res       Date:  2009-02-17       Impact factor: 16.971

View more
  54 in total

Review 1.  Epigenetic regulation of human retinoblastoma.

Authors:  Usha Singh; Manzoor Ahmad Malik; Sandeep Goswami; Swati Shukla; Jasbir Kaur
Journal:  Tumour Biol       Date:  2016-09-17

2.  Tumour suppressors: A microdependency of importance?

Authors:  Darren J Burgess
Journal:  Nat Rev Cancer       Date:  2012-10       Impact factor: 60.716

Review 3.  Systems genetics in "-omics" era: current and future development.

Authors:  Hong Li
Journal:  Theory Biosci       Date:  2012-11-09       Impact factor: 1.919

4.  Inactivation of p53 is insufficient to allow B cells and B-cell lymphomas to survive without Dicer.

Authors:  Clare M Adams; Christine M Eischen
Journal:  Cancer Res       Date:  2014-05-19       Impact factor: 12.701

5.  microRNA-17~92 is a powerful cancer driver and a therapeutic target.

Authors:  Hyun Yong Jin; Maoyi Lai; Changchun Xiao
Journal:  Cell Cycle       Date:  2014-01-13       Impact factor: 4.534

Review 6.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

Review 7.  The genomic landscape of retinoblastoma: a review.

Authors:  Brigitte L Thériault; Helen Dimaras; Brenda L Gallie; Timothy W Corson
Journal:  Clin Exp Ophthalmol       Date:  2013-05-22       Impact factor: 4.207

Review 8.  Expression profiles and prognostic value of miRNAs in retinoblastoma.

Authors:  Lara Elis Alberici Delsin; Karina Bezerra Salomao; Julia Alejandra Pezuk; Maria Sol Brassesco
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-22       Impact factor: 4.553

Review 9.  Biomarkers in retinoblastoma.

Authors:  Jie Sun; Hui-Yu Xi; Qing Shao; Qing-Huai Liu
Journal:  Int J Ophthalmol       Date:  2020-02-18       Impact factor: 1.779

10.  A Biogenesis Step Upstream of Microprocessor Controls miR-17∼92 Expression.

Authors:  Peng Du; Longfei Wang; Piotr Sliz; Richard I Gregory
Journal:  Cell       Date:  2015-08-06       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.